These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 22340019

  • 1. Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease.
    Chatterjee A, Shah M, D'Souza AO, Bechtel B, Crater G, Dalal AA.
    Respir Res; 2012 Feb 17; 13(1):15. PubMed ID: 22340019
    [Abstract] [Full Text] [Related]

  • 2. Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients.
    Ismaila A, Corriveau D, Vaillancourt J, Parsons D, Dalal A, Su Z, Sampalis JS.
    Curr Med Res Opin; 2014 Jul 17; 30(7):1427-36. PubMed ID: 24666181
    [Abstract] [Full Text] [Related]

  • 3. Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease.
    Dalal AA, Roberts MH, Petersen HV, Blanchette CM, Mapel DW.
    Int J Chron Obstruct Pulmon Dis; 2010 Dec 31; 6():13-22. PubMed ID: 21311689
    [Abstract] [Full Text] [Related]

  • 4. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD.
    Dalal AA, Candrilli SD, Davis KL.
    Manag Care; 2011 Aug 31; 20(8):46-50, 53-5. PubMed ID: 21887993
    [Abstract] [Full Text] [Related]

  • 5. Clinical and economic outcomes in an observational study of COPD maintenance therapies: multivariable regression versus propensity score matching.
    Roberts MH, Dalal AA.
    Int J Chron Obstruct Pulmon Dis; 2012 Aug 31; 7():221-33. PubMed ID: 22500122
    [Abstract] [Full Text] [Related]

  • 6. Clinical and economic outcomes associated with the use of fluticasone propionate 250 mcg and salmeterol 50 mcg combination versus tiotropium bromide 18 mcg as initial maintenance treatment for chronic obstructive pulmonary disease in managed care.
    Bell CF, Coutinho AD, Farrelly E, Lokhandwala T, Landsman-Blumberg P.
    J Med Econ; 2018 Jun 31; 21(6):629-638. PubMed ID: 29577787
    [Abstract] [Full Text] [Related]

  • 7. Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD.
    Dalal AA, Shah MB, D'Souza AO, Lunacsek OE, Nagar SP, Crater GD.
    Respir Res; 2012 May 31; 13(1):41. PubMed ID: 22651541
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of combination fluticasone propionate-salmeterol 250/50 microg versus salmeterol in severe COPD patients.
    Dalal AA, St Charles M, Petersen HV, Roberts MH, Blanchette CM, Manavi-Zieverink K.
    Int J Chron Obstruct Pulmon Dis; 2010 Aug 09; 5():179-87. PubMed ID: 20714371
    [Abstract] [Full Text] [Related]

  • 9. Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy.
    Dalal AA, Shah M, D'Souza AO, Crater GD.
    Respir Med; 2012 Jun 09; 106(6):829-37. PubMed ID: 22425138
    [Abstract] [Full Text] [Related]

  • 10. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study.
    Jung KS, Park HY, Park SY, Kim SK, Kim YK, Shim JJ, Moon HS, Lee KH, Yoo JH, Lee SD, Korean Academy of Tuberculosis and Respiratory Diseases study group, Korea Chronic Obstructive Pulmonary Disease study group.
    Respir Med; 2012 Mar 09; 106(3):382-9. PubMed ID: 21975275
    [Abstract] [Full Text] [Related]

  • 11. Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population.
    Dalal AA, Shah M, D'Souza AO, Chaudhari S, Crater G.
    Int J Chron Obstruct Pulmon Dis; 2012 Mar 09; 7():11-9. PubMed ID: 22315518
    [Abstract] [Full Text] [Related]

  • 12. Healthcare costs associated with initial maintenance therapy with fluticasone propionate 250 μg/salmeterol 50 μg combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPD.
    Dalal AA, Petersen H, Simoni-Wastila L, Blanchette CM.
    J Med Econ; 2009 Mar 09; 12(4):339-47. PubMed ID: 19827993
    [Abstract] [Full Text] [Related]

  • 13. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM, Akazawa M, Dalal A, Simoni-Wastila L.
    Am J Geriatr Pharmacother; 2008 Aug 09; 6(3):138-46. PubMed ID: 18775388
    [Abstract] [Full Text] [Related]

  • 14. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.
    Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M, Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium.
    Ann Intern Med; 2007 Apr 17; 146(8):545-55. PubMed ID: 17310045
    [Abstract] [Full Text] [Related]

  • 15. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.
    Hanania NA, Crater GD, Morris AN, Emmett AH, O'Dell DM, Niewoehner DE.
    Respir Med; 2012 Jan 17; 106(1):91-101. PubMed ID: 22040533
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.
    Roberts M, Mapel D, Petersen H, Blanchette C, Ramachandran S.
    J Med Econ; 2011 Jan 17; 14(6):769-76. PubMed ID: 21942463
    [Abstract] [Full Text] [Related]

  • 18. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
    Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ.
    Thorax; 2008 Jul 17; 63(7):592-8. PubMed ID: 18245142
    [Abstract] [Full Text] [Related]

  • 19. Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies.
    Delea TE, Hagiwara M, Dalal AA, Stanford RH, Blanchette CM.
    Curr Med Res Opin; 2009 Jan 17; 25(1):1-13. PubMed ID: 19210134
    [Abstract] [Full Text] [Related]

  • 20. Benefits of adding fluticasone propionate/salmeterol to tiotropium in COPD: a meta-analysis.
    Liu Y, Shi H, Sun X, Zhang D, Zhang Y, Yang K, Mi L, Li M.
    Eur J Intern Med; 2014 Jun 17; 25(5):491-5. PubMed ID: 24816076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.